When Appetite Became a Platform - how GLP-1s are rewiring food, insurance, and healthcare, and why 2025 feels different
GLP-1 drugs aren’t just changing bodies — they’re rerouting demand. They’re forcing food companies, insurers, and healthcare systems to confront a question they were never built to answer: what happens when prevention finally works, but the system isn’t designed to absorb it?
The other day, I was scrolling through my YouTube feed when a video stopped me mid-thumb:
“GLP-1 agonists in bodybuilding and weight management.”
The clip featured a fitness influencer — a former competitive bodybuilder with nearly four million subscribers — explaining how GLP-1 drugs could revolutionize the fitness industry, helping elite athletes achieve their physiques more efficiently.
I paused.
A “weight-loss” drug… for the leanest people on the planet?
The idea didn’t sit easily. But then other examples surfaced, uninvited.
I thought of myself — someone who never paid a penny for cable television — now planning entire staycations around a running list of Netflix shows I “need” to binge once life slows down. I thought of my husband, who barely uses ride-hailing for transportation, yet opens Uber several times a week — not for cars, but for food and grocery delivery.
None of these tools replaced the old ones outright. They didn’t invent television or transportation or eating. They simply rerouted demand — quietly, efficiently, at scale.
That’s when it clicked.
What we’re witnessing with GLP-1 drugs isn’t just another pharmaceutical breakthrough. It’s the emergence of a new platform — one that doesn’t treat appetite as a personal failing to be disciplined away, but as a system to be recalibrated. And like every true platform disruption before it, once demand changes, everything built around it has to respond.
Why GLP-1s Behave Like a Platform
Most medical breakthroughs work vertically. They improve outcomes within a system — a better cancer drug, a safer blood thinner, a more precise antidepressant. The rest of the world barely notices.
GLP-1 drugs work horizontally.
They don’t just change health markers; they change behavior. And not through motivation, discipline, or education — but through appetite itself.
Biologically, that difference matters. Unlike earlier weight-management drugs that relied on stimulants, metabolic acceleration, or blunt appetite suppression, GLP-1 agonists mimic a naturally occurring gut hormone that regulates satiety across multiple systems at once. GLP-1 receptors are active in the digestive tract and pancreas — where they slow gastric emptying and improve insulin signaling — but also in the brain regions that govern hunger, impulse control, and reward.¹² This is why their effects feel unfamiliar to patients: they don’t produce tension or restraint. They alter perception.
Clinically, many users describe a reduction in what researchers now call food noise — the persistent cognitive preoccupation with eating.³ Culturally, that translates into something quietly radical. Cravings lose urgency. Portions feel sufficient without effort. The internal monologue — Should I? Shouldn’t I? — softens, not because it’s been conquered, but because it’s no longer constantly triggered.
That’s what makes GLP-1s behave less like a traditional drug and more like a platform.
Platforms don’t replace products; they reroute demand. Uber didn’t improve cars. Netflix didn’t make television smarter. They changed when, how, and how much people consumed — and in doing so, destabilized everything built around the old patterns.
GLP-1s do the same thing to appetite.
They quietly reduce volume — of calories, of cravings, of consumption. And when millions of people begin eating less, not because they are trying harder but because they want less, the effects compound far beyond individual bodies.
This is why GLP-1s feel disruptive in a way diet plans never did. Diets asked people to fight demand. These drugs recalibrate demand itself.
And once demand shifts, entire industries — food, insurance, healthcare — are forced to renegotiate their value propositions. Not because consumers suddenly became more disciplined, but because the underlying signal they were built to respond to has changed.
That’s the platform moment.
The First Domino: When Demand Changes, Incumbents Follow
Platform disruptions don’t destroy industries overnight. They force them to adapt — awkwardly at first, then structurally.
When Netflix shifted how people consumed television, cable didn’t disappear. It merged. Bundles collapsed and reassembled. Comcast launched Peacock. Disney pulled content from Netflix to build Disney+.⁴⁵ Streaming didn’t replace television; it rewrote how it was packaged, priced, and consumed.
When Uber changed how people summoned a ride, taxis didn’t vanish either. They built apps. Cities integrated taxi fleets into ride-hailing platforms. In New York, traditional yellow cabs became bookable through Uber itself.⁶ Uber didn’t eliminate taxis; it forced them to meet users where demand had already moved.
In both cases, the disruption wasn’t about quality. It was about friction removal. Once consumers experienced on-demand access, the old model stopped making sense — even if it technically still worked.
GLP-1s apply that same logic to food.
For decades, the food industry operated on a stable assumption: appetite would stay loud. Products were engineered for craving, convenience, and repetition. Growth depended on volume — more snacks, more servings, more moments to eat.
As appetite quiets, behavior shifts. People buy fewer snacks. They linger less in grocery aisles. Impulse purchases decline. Highly processed, hyper-palatable foods lose their advantage — not because consumers have become more disciplined, but because the biological demand signal has weakened.
And just like cable and taxis, incumbents are already responding.
Large food companies are reformulating products and rebalancing portfolios — higher protein, higher fiber, lower sugar. Portion sizes, once framed as a concession, are being rebranded as intentional. Snack categories are fragmenting: fewer “treats,” more “functional” foods promising fullness, balance, or sustained energy.⁷
The industry isn’t being disrupted because people suddenly learned how to eat better. It’s being disrupted because a growing share of consumers physically cannot — and no longer want to — consume at the scale the system was built for.
Netflix didn’t teach viewers to watch less television.
Uber didn’t teach riders to hate taxis.
GLP-1s aren’t teaching people to eat better.
They’re changing how much demand exists — and once that happens, every incumbent has to adapt.
Insurance and the Netflix Problem
Cable television and health insurance share a quiet business model: both are subscription systems that depend on underuse. Cable works because most subscribers pay for dozens of channels they rarely watch. Insurance works because most members pay premiums and, in any given year, don’t get seriously sick.
Netflix disrupted cable not by offering better television, but by changing how value was consumed. A low-friction, flat monthly fee normalized heavy usage. Watching more didn’t cost more. Underuse stopped being the default. The bundle didn’t collapse because content changed, but because consumption did.
GLP-1 drugs create the same problem for insurance.
They shift obesity from an advice problem to a treatable, preventable risk — increasingly backed by evidence that sustained use can reduce downstream cardiovascular events.⁸ But prevention here doesn’t look like a one-time intervention. It looks like a subscription: continuous, predictable spending for a large population.
That’s why insurers resist — not out of denial, but design.
First, the costs are immediate while the savings are delayed. GLP-1s require monthly spending now, while their biggest financial benefits arrive years later, often beyond the window insurers use to price premiums and manage budgets.
Second, the savings are often captured by someone else. In a fragmented system where people change jobs and plans frequently, one insurer may fund GLP-1 therapy while another benefits later when a heart attack never happens.
Third, scale changes the math. Even when a therapy is cost-effective over a lifetime, covering it broadly can strain annual budgets. GLP-1s apply to a large share of adults, shifting the challenge from value to affordability — with upward pressure on premiums and trade-offs across benefits.⁹¹⁰
This is the Netflix dilemma, translated into healthcare finance: a system built on underuse confronted with a tool that normalizes prevention. Once high utilization becomes rational, systems designed around scarcity begin to crack.
The tension isn’t whether GLP-1s work. It’s whether our insurance model is built to pay for health before it breaks.
Healthcare After Gatekeeping Loses Its Monopoly
Uber didn’t disrupt transportation by replacing taxis. It disrupted transportation by unlocking supply.
Once anyone with a car could become a driver, capacity expanded dramatically. Transportation shifted from a centralized service to a distributed, on-demand system. The same infrastructure then extended naturally into food and grocery delivery — not because Uber changed industries, but because once demand could be met instantly, supply became modular.
GLP-1s introduce a similar shift in healthcare.
They don’t replace physicians or procedures. They redistribute intervention — earlier, broader, and more continuously. Where healthcare once concentrated resources at moments of failure, GLP-1s enable action before disease hardens into diagnosis.
Many of the most expensive and invasive treatments in modern medicine — bariatric surgery, advanced diabetes management, cardiac interventions — are downstream responses to prolonged metabolic strain. GLP-1s don’t eliminate the need for these services, but they reduce the volume of patients who ever reach that stage.
The disruption, then, is not substitution. It’s reallocation — of timing, intensity, and responsibility across the care continuum.
Healthcare systems now face an adaptation challenge similar to taxis after Uber: how to move resources upstream without hollowing out the capacity to treat advanced disease. This demands a more personalized, dynamic model of care — one that intervenes earlier for some, later for others, and no longer treats restraint as a prerequisite for treatment.
GLP-1s don’t signal the end of traditional care. They signal a reordering of timing, supply, and responsibility — from reacting to breakdowns to managing trajectories.
That’s the Uber moment in healthcare: when access expands, and the system must decide how to adapt rather than resist.
The Collision Point
By 2025, the disruption is no longer theoretical. It’s simultaneous.
Food companies are adjusting to quieter appetites. Insurers are resisting a preventive model they can’t easily finance. Healthcare systems are rethinking when — and for whom — intervention should begin. Each system is responding rationally on its own terms. Together, they are out of sync.
This is why GLP-1s feel unusually visible right now. Not because they are new, but because they force multiple industries to confront the same question at once: what happens when prevention finally works, but the system isn’t built to absorb it?
For individuals, this creates cognitive dissonance. A drug that makes eating easier is framed as “cheating.” A medical intervention that prevents disease feels morally suspect because it arrives before suffering does.
For industries, the tension is structural. Food must adapt to reduced volume. Insurance must reconcile long-term value with short-term budgets. Healthcare must shift from reacting to failure toward managing trajectories — without abandoning the capacity to treat those who still arrive late.
And for society, the stakes are larger still. A tool that could reduce chronic disease at scale risks widening inequities if access remains uneven. A technology that normalizes prevention challenges long-standing ideas about effort, deservingness, and responsibility.
Moments like this are inherently unstable. When biology moves faster than institutions, friction follows. We’ve seen it before — when streaming outpaced regulation, when ride-sharing outgrew labor frameworks.
GLP-1s mark a similar inflection point, but with higher stakes. This isn’t about how we watch, move, or order dinner. It’s about how we define health, allocate care, and decide when intervention is allowed.
The question facing 2025 isn’t whether GLP-1s will reshape the system. They already are.
The question is whether individuals, industries, and institutions can adapt quickly enough to turn disruption into durable benefit — rather than letting misalignment harden into inequality.
For now, GLP-1s sit at an inflection point. Not a universal solution, not a moral verdict — but a platform whose full consequences are still unfolding. Whether one uses them or not, their significance lies elsewhere: in the possibility that a problem modern societies have struggled to manage for decades might finally shift from being endlessly treated to meaningfully prevented.
That transition — from reacting to breakdowns to managing trajectories — may prove to be GLP-1s’ most lasting legacy.
Endnotes
- Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism, 2018.
- Holst JJ. The Physiology of Glucagon-Like Peptide 1. Physiological Reviews, 2007.
- Wharton S et al. Perceptions of “Food Noise” in Patients Using GLP-1 Receptor Agonists. Obesity Reviews, 2023.
- Comcast Corporation. Peacock Launch and Strategy Overview, 2020.
- Disney Company. Disney+ Investor Day Presentations, 2019–2021.
- Uber Technologies. Uber–NYC Taxi Integration Announcement, 2022.
- NielsenIQ. Changing Food Purchasing Patterns in the Era of GLP-1 Adoption, 2024.
- SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity. New England Journal of Medicine, 2023.
- Institute for Clinical and Economic Review (ICER). Anti-Obesity Medications: Final Evidence Report, 2023.
- Employee Benefit Research Institute (EBRI). Modeling the Impact of GLP-1 Coverage on Employer Health Plans, 2024.
